💡 Led by enGenes Biotech, the system can produce significant amounts of Protein A, essential for monoclonal antibodies.
🔬 The innovative process decouples protein production from cell growth, tackling challenges like genetic drift.
🤖 Future plans include scaling up to larger production facilities, enhancing bioproduction’s accessibility and eco-friendliness.
Introduction:
A recent advancement in biomanufacturing has emerged from an Austrian consortium that has developed the first fully integrated and automated process for producing recombinant proteins using *E. coli*. This new approach aims to streamline the production of Protein A, a key component in monoclonal antibody manufacturing.
- The project, led by enGenes Biotech, has resulted in a lab-scale prototype capable of producing significant amounts of Protein A.
- The production scale is currently at one liter, with plans to expand into larger biomanufacturing facilities within two years, pending investment.
- The traditional bottleneck in automating *E. coli* production has been genetic drift; however, the consortium has countered this issue with innovative technology.
- The proprietary enGenes eXpress technology decouples protein production from cell growth, preventing adaptive evolution that hampers output.
- Collaboration among various Austrian companies highlights a focus on reducing ecological impacts and promoting efficient bioproduction methods.
Conclusion:
The development of a fully automated process for *E. coli*-based protein production represents a significant step forward in biomanufacturing. With potential for scalable applications and ecological sustainability, this innovation could reshape the landscape of recombinant protein production, making it more accessible and efficient.
